{
    "root": "4a13e20b-6a21-4d45-a159-a2add4ce215e",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "HUMAN PRESCRIPTION DRUG LABEL",
    "name": "FENOFIBRATE",
    "value": "20250528",
    "ingredients": [
        {
            "name": "FENOFIBRATE",
            "code": "U202363UOS"
        },
        {
            "name": "CROSPOVIDONE",
            "code": "2S7830E561"
        },
        {
            "name": "D&C YELLOW NO. 10",
            "code": "35SW5USQ3G"
        },
        {
            "name": "FD&C BLUE NO. 2",
            "code": "L06K8R7DQK"
        },
        {
            "name": "FD&C YELLOW NO. 6",
            "code": "H77VEI93A8"
        },
        {
            "name": "HYPROMELLOSE 2910 (6 MPA.S)",
            "code": "0WZ8WG20P6"
        },
        {
            "name": "LACTOSE MONOHYDRATE",
            "code": "EWQ57Q8I5X"
        },
        {
            "name": "LECITHIN, SOYBEAN",
            "code": "1DI56QDM62"
        },
        {
            "name": "MAGNESIUM STEARATE",
            "code": "70097M6I30"
        },
        {
            "name": "MICROCRYSTALLINE CELLULOSE",
            "code": "OP1R32D61U"
        },
        {
            "name": "POLYVINYL ALCOHOL, UNSPECIFIED",
            "code": "532B59J990"
        },
        {
            "name": "SILICON DIOXIDE",
            "code": "ETJ7Z6XBU4"
        },
        {
            "name": "SODIUM LAURYL SULFATE",
            "code": "368GB5141J"
        },
        {
            "name": "TALC",
            "code": "7SEV7J4R1U"
        },
        {
            "name": "TITANIUM DIOXIDE",
            "code": "15FIX9V2JP"
        },
        {
            "name": "XANTHAN GUM",
            "code": "TTV12P4NEE"
        }
    ],
    "indications": "fenofibrate peroxisome proliferator-activated receptor ( ppar ) alpha agonist indicated adjunct diet reduce elevated ldl-c , total-c , tg apo b , increase hdl- c adult patients primary hypercholesterolemia mixed dyslipidemia ( 1.1 ) . treatment adult patients severe hypertriglyceridemia ( 1.2 ) . limitations : fenofibrate shown reduce coronary heart disease morbidity mortality patients type 2 diabetes mellitus ( 5.1 ) .",
    "contraindications": "primary hypercholesterolemia mixed dyslipidemia : initial dose 160 mg daily ( 2.2 ) . severe hypertriglyceridemia : initial dose 54 160 mg daily . maximum dose 160 mg ( 2.3 ) . renally impaired patients : initial dose 54 mg daily ( 2.4 ) . geriatric patients : select dose basis renal function ( 2.5 ) given meals ( 2.1 ) .",
    "warningsAndPrecautions": "fenofibrate tablets , usp available two strengths : 54 mg light yellow yellow , oval shaped , film coated tablets , debossed `` ls `` one side `` 214 `` side . bottles 90 tablets child-resistant closure ( ndc 70756-214-90 ) . bottles 500 tablets ( ndc 70756-214-51 ) . 160 mg white white , oval shaped , film coated tablets debossed `` ls `` one side `` 215 `` side bottles 90 tablets child-resistant closure ( ndc 70756-215-90 ) . bottles 500 tablets ( ndc 70756-215-51 ) . storage store 20°c 25°c [ 68°f 77°f ] [ usp controlled room temperature ] . keep reach children . protect moisture .",
    "adverseReactions": "fenofibrate tablet contraindicated : patients severe renal impairment , including receiving dialysis [ pharmacology ( 12.3 ) ] . patients active liver disease , including primary biliary cirrhosis unexplained persistent liver function abnormalities [ ( 5.2 ) ] patients preexisting gallbladder disease [ ( 5.5 ) ] . nursing mothers [ ( 8.2 ) ] patients known hypersensitivity fenofibrate fenofibric acid [ ( 5.9 ) ] .",
    "indications_original": "Fenofibrate is peroxisome proliferator-activated receptor (PPAR) alpha agonist indicated as an adjunct to diet To reduce elevated LDL-C, Total-C, TG and      Apo B, and to increase HDL- C in adult patients with primary      hypercholesterolemia or mixed dyslipidemia ( 1.1 ). For treatment of adult patients with      severe hypertriglyceridemia ( 1.2 ). Limitations of Use: Fenofibrate was not shown to reduce coronary heart disease morbidity and mortality in patients with type 2 diabetes mellitus ( 5.1 ).",
    "contraindications_original": "Primary hypercholesterolemia or mixed      dyslipidemia: Initial dose of 160 mg once daily ( 2.2 ). Severe hypertriglyceridemia: Initial dose      of 54 to 160 mg once daily. Maximum dose is 160 mg ( 2.3 ). Renally impaired patients: Initial dose      of 54 mg once daily ( 2.4 ). Geriatric patients: Select the dose on      the basis of renal function ( 2.5 ) Should be given with meals ( 2.1 ).",
    "warningsAndPrecautions_original": "Fenofibrate tablets, USP are available in two strengths:\n                  54 mg light yellow to yellow, oval shaped, film coated tablets, debossed with \"LS\" on one side and \"214\" on the other side.\n                  Bottles of 90 tablets with child-resistant closure (NDC 70756-214-90).\n                  Bottles of 500 tablets (NDC 70756-214-51).\n                  160 mg white to off white, oval shaped, film coated tablets debossed with \"LS\" on one side and \"215\" on the other side \n                  Bottles of 90 tablets with child-resistant closure (NDC 70756-215-90).\n                  Bottles of 500 tablets (NDC 70756-215-51).\n                  \n                     Storage\n                  \n                  Store at 20°C to 25°C [68°F to 77°F] [See USP Controlled Room Temperature]. Keep out of the reach of children. Protect from moisture.",
    "adverseReactions_original": "Fenofibrate tablet is contraindicated in: \n                  \n                     patients with severe renal impairment, including those receiving dialysis [see Clinical Pharmacology (12.3)] .\n                     patients with active liver disease, including those with primary biliary cirrhosis and unexplained persistent liver function abnormalities [see Warnings and Precautions (5.2)]\n                     \n                     patients with preexisting gallbladder disease [see Warnings and Precautions (5.5)] .\n                     nursing mothers [see Use in Specific Populations (8.2)]\n                     \n                     patients with known hypersensitivity to fenofibrate or fenofibric acid [see Warnings and Precautions (5.9)]."
}